	US 12,227,583 B2
	Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
Cheng Liao, Jiangsu (CN); Zupeng Xu, Jiangsu (CN); Jiahua Jiang, Jiangsu (CN); Xin Ye, Jiangsu (CN); and Lianshan Zhang, Jiangsu (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN)
Appl. No. 17/278,259
Filed by Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN)
PCT Filed Sep. 25, 2019, PCT No. PCT/CN2019/107787 § 371(c)(1), (2) Date Mar. 19, 2021, PCT Pub. No. WO2020/063660, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 201811128669.3 (CN), filed on Sep. 26, 2018; and application No. 201811417666.1 (CN), filed on Nov. 26, 2018.
Prior Publication US 2021/0355229 A1, Nov. 18, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01)]

17 Claims

1. An anti-OX40 antibody or antigen-binding fragment thereof, wherein:

the anti-OX40 antibody or antigen-binding fragment thereof comprises:

i) HCDR1 as shown in SEQ ID NO: 11, HCDR2 as shown in SEQ ID NO: 33, SEQ ID NO: 12 or SEQ ID NO: 34, and HCDR3 as shown in SEQ ID NO: 13, and LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 14, 15 and 16 respectively; or

ii) HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 11, 12 and 13 respectively, and LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 14, 15 and 16 respectively.